Assay is delighted to have advised the shareholders in National Slimming and Cosmetic Clinics (“NSC”), the UK’s largest chain of medical weight-loss clinics, on the sale of the business to Harwood Private Equity, a leading investor in the UK lower mid-market.

NSC provides private doctor-led non-surgical weight loss therapies, with a focus on regulated prescription drugs administered and monitoring by doctors. It controls a chain of clinics across the country, each accredited by the Care Quality Commission and treats more than 60,000 patients per annum.

The transaction completed on the 28^th September 2018 and the NSC shareholders were advised by Assay Corporate Finance lead by Mike Simson, with legal advice provided by Bracher Rawlins.

Jeffrey Baker, the shareholder in NSC who led the exit negotiations said, “The team at Assay did a superb job of getting us ready for sale, bringing Harwood Private Equity to the transaction and managing us through the exit process.”

Mike Simson of Assay commented, “We thank Harwood for the professional manner in which they carried out their investment process and wish them every success with their investment in NSC. The previous owners did an excellent job in growing the business into the UK’s largest privately owned medical weight loss group in readiness for the next phase of its development.”

About Assay Corporate Finance

Assay combines extensive transaction experience with an analytical and quantitative framework in order to transfer its knowledge to business owners.

Assay’s unique hybrid offering blends the organisational transformation elements of consulting with the strategic elements of corporate finance. They specialise in getting investors or acquirers to value their business from a strategic perspective by focusing on the valuation multiple, instead of treating it as a simple financial transaction.

With offices in London and Birmingham, Assay is a UK member firm of IMAP which gives it unrivalled international reach with M&A offices in 39 countries.